Mazaticol for Treating Parkinson

Yoshiki Niimi, Tatsuro Mutoh

Research output: Chapter in Book/Report/Conference proceedingChapter


Mazaticol, 6, 6, 9-trimethyl-9-azabicyclo[3, 3, 1]non-3β-yl-α, α-di-(2-thienyl) glycolate hydrochloride monohydrate, was developed by Tanabe Seiyaku Co. LTD. in1970s and started selling in 1978 in Japan. This agent has an anticholinergic activity in the central nervous system as the same degree of well-known anticholinergic medicine, trihexyphenidyl. Mazaticol and other anticholinergic agents are considered to block the muscarinic acetylcholine receptors and cholinergic nerve activity. Mazaticol has an affinity to M1 and M2 muscarinic acetylcholine receptor and had less peripheral activity compared to other anticholinergic agents. In the animal experiments, mazaticol exhibited inhibitory effects on dopamine uptake in the striatal nerve terminal. As for clinical indication, mazaticol is applied mainly to a psychotropic drug-induced parkinsonian syndrome. Many clinical evaluations showed efficacy of mazaticol is almost as same as the other anticholinergic agents. But mazaticol showed the improvement of symptoms for the cases in which other drugs had no effects. However, current clinical studies on mazaticol are not enough, especially for the idiopathic parkinsonian disease.

Original languageEnglish
Title of host publicationNeuroPsychopharmacotherapy
PublisherSpringer International Publishing
Number of pages12
ISBN (Electronic)9783030620592
ISBN (Print)9783030620585
Publication statusPublished - 01-01-2022

All Science Journal Classification (ASJC) codes

  • General Pharmacology, Toxicology and Pharmaceutics
  • General Medicine


Dive into the research topics of 'Mazaticol for Treating Parkinson'. Together they form a unique fingerprint.

Cite this